Dr. Wang founded Lyvgen and dedicated its research and development of world leading Immuno-Oncology (IO) therapeutics to meet patients needs, contributing to the better understanding of tumor immuno-infiltration, tumor immunity and structure and function of IO therapeutic antibodies. Prior to founding Lyvgen, Dr. Wang worked at Abbott/ AbbVie for 22 years in Oncology R&D and led research teams to deliver multiple antibody protein drugs into clinical development.
Research and Development
Since our first innovative agonist anti-CD137/4-1BB antibody developed in 2017, our global IO pipeline has grown substantially, exemplified by a series of bispecific Abs entering our in-house GMP-CMC manufacture phase. My goal is to transform scientific innovation into practice-changing cancer drugs by working closely with experienced Dr.Jieyi Wang and our talented down-to-earth team members.
Together with other Lyvgeners, we believe in the benefits and exciting future of therapeutic antibody for cancer treatment. Our passion is to effectively channel the many different factors required for product commercial manufacturing, such as impurity management, scalability, stability and availability of raw materials. Our confidence and optimism comes from strong team spirit, intelligent and hard working.
Tony Tang, MD, Ph.D.
Clinical DevelopmentLyvgen is a clinical stage biotech company focused on immunotherapy for cancer patients. Lead by an experienced management team, we are trying to bring the cutting-edge new medicines into the market through innovative science and effective management. Currently, we have already developed an early pipeline of innovative antibodies including PD-1 antibody and a unique set of proprietary co-stimulation agonist antibodies with the potential to become first-in-class and best-in-class biotherapeutics. I joined Lyvgen in November 2019 as the head of clinical development and safety. Prior to joining Lyvgen, I served at various companies of different clinical development and safety roles, including Genentech, Fibrogen, Cytomx.I received my MD from Fudan University, and PhD in Microbiology & Immunology from University of Southern California.
Lynn Jiang, Ph.D.
Vice President Clinical Operation
Though Lyvgen is a startup biopharma company, it is committed to deliver innovative medicines to help millions of cancer patients around the world. Lyvgen’s mission aligns with my life-long passion. Ever since college, my education and work experiences have been focused on the drug discovery and development. Lyvgen’s culture is science-driving and delivery-oriented which attracts and retains talented professionals at every level. Lyvgen’s management is efficient and effective, and every role takes its accountabilities. I have faith on Lyvgen to successfully innovate new drugs that tackle diseases and ultimately save patients’ lives, or improve their quality of life. I enjoy my expertise can be put in good use, and feel fulfill while career development growing with the success of Lyvgen. As a clinical operations lead, I am accountable for overall operational execution to ensure Lyvgen’s mission accomplished, and responsible for setting executional priorities and strategic clinical operational alignment with clinical programs.
Senior Director General Operation
As one of the earliest members of Lyvgen family, I experienced the dynamic progress of Lyvgen. Our team provides stability to the company. We maintain the infrastructures that work to accomplish the needs of the others in Lyvgen to create the larger outcome.
Director Human Resource
By incorporating my knowledge of best HR practices into my daily life, I effectively support our company strategic goals and direction, especially by recruiting the talent to catch up the high growth rate of Lyvgen. I'm also responsible for diversity and inclusion initiatives to build positive relationships, balancing results with a concern for the needs of others.
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.